Cargando…

Oncological Risk in Autologous Stem Cell Donation for Novel Tissue-Engineering Approaches to Postmastectomy Breast Regeneration

Adipose tissue engineering using adipose-derived stem cells (ADSCs) has emerged as an opportunity to develop novel approaches to postmastectomy breast reconstruction with the potential for an autologous tissue source with a natural appearance and texture. As of yet, the role of ADSCs in breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Halloran, Niamh, Khan, Sonja, Gilligan, Katie, Dwyer, Roisin, Kerin, Michael, Lowery, Aoife
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753512/
https://www.ncbi.nlm.nih.gov/pubmed/31555047
http://dx.doi.org/10.1177/1178223419864896
_version_ 1783452902687244288
author O’Halloran, Niamh
Khan, Sonja
Gilligan, Katie
Dwyer, Roisin
Kerin, Michael
Lowery, Aoife
author_facet O’Halloran, Niamh
Khan, Sonja
Gilligan, Katie
Dwyer, Roisin
Kerin, Michael
Lowery, Aoife
author_sort O’Halloran, Niamh
collection PubMed
description Adipose tissue engineering using adipose-derived stem cells (ADSCs) has emerged as an opportunity to develop novel approaches to postmastectomy breast reconstruction with the potential for an autologous tissue source with a natural appearance and texture. As of yet, the role of ADSCs in breast cancer development and metastasis is not completely understood; therefore, we must consider the oncological safety of employing an autologous source of ADSCs for use in breast regeneration. This study investigated the regenerative properties of ADSCs isolated from breast cancer patients, including those who had received neoadjuvant chemotherapy, and noncancer controls. The ADSCs were characterised for several parameters central to tissue regeneration, including cell viability, proliferation, differentiation potential, and cytokine secretion. A stem cell population was isolated and confirmed by flow cytometry and multilineage differentiation. There was no difference in cell phenotype or surface antigen expression between ADSCs from different sources. Adipose-derived stem cells isolated from the breast of cancer patients exhibited reduced adipogenic differentiation potential compared with ADSCs from other sources. The greatest degree of adipogenic differentiation was observed in ADSCs isolated from the subcutaneous abdominal fat of noncancer controls. The proliferation rate of ADSCs isolated from the breast of cancer patients was increased compared with other sources; however, it was decreased in ADSCs isolated from breast cancer patients who had recently been treated with neoadjuvant chemotherapy. A number of cytokines were detected in the cell conditioned media of ADSCs from different sources, including matrix metalloproteinase-2 (MMP-2), which was detected at higher levels in the secretome of ADSCs from breast cancer patients compared with noncancer controls. This study provides important information relating to the suitability of ADSCs as an autologous cell source for adipose tissue engineering in postcancer reconstruction. Results indicate that while the surface phenotype does not differ, the differentiation capacity, proliferative rate, and secreted cytokine profile are affected by the presence or treatment of breast cancer. These findings support further investigation into the regenerative potential of these ADSCs, if they are to be considered in clinical reconstructive strategies.
format Online
Article
Text
id pubmed-6753512
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-67535122019-09-25 Oncological Risk in Autologous Stem Cell Donation for Novel Tissue-Engineering Approaches to Postmastectomy Breast Regeneration O’Halloran, Niamh Khan, Sonja Gilligan, Katie Dwyer, Roisin Kerin, Michael Lowery, Aoife Breast Cancer (Auckl) Original Research Adipose tissue engineering using adipose-derived stem cells (ADSCs) has emerged as an opportunity to develop novel approaches to postmastectomy breast reconstruction with the potential for an autologous tissue source with a natural appearance and texture. As of yet, the role of ADSCs in breast cancer development and metastasis is not completely understood; therefore, we must consider the oncological safety of employing an autologous source of ADSCs for use in breast regeneration. This study investigated the regenerative properties of ADSCs isolated from breast cancer patients, including those who had received neoadjuvant chemotherapy, and noncancer controls. The ADSCs were characterised for several parameters central to tissue regeneration, including cell viability, proliferation, differentiation potential, and cytokine secretion. A stem cell population was isolated and confirmed by flow cytometry and multilineage differentiation. There was no difference in cell phenotype or surface antigen expression between ADSCs from different sources. Adipose-derived stem cells isolated from the breast of cancer patients exhibited reduced adipogenic differentiation potential compared with ADSCs from other sources. The greatest degree of adipogenic differentiation was observed in ADSCs isolated from the subcutaneous abdominal fat of noncancer controls. The proliferation rate of ADSCs isolated from the breast of cancer patients was increased compared with other sources; however, it was decreased in ADSCs isolated from breast cancer patients who had recently been treated with neoadjuvant chemotherapy. A number of cytokines were detected in the cell conditioned media of ADSCs from different sources, including matrix metalloproteinase-2 (MMP-2), which was detected at higher levels in the secretome of ADSCs from breast cancer patients compared with noncancer controls. This study provides important information relating to the suitability of ADSCs as an autologous cell source for adipose tissue engineering in postcancer reconstruction. Results indicate that while the surface phenotype does not differ, the differentiation capacity, proliferative rate, and secreted cytokine profile are affected by the presence or treatment of breast cancer. These findings support further investigation into the regenerative potential of these ADSCs, if they are to be considered in clinical reconstructive strategies. SAGE Publications 2019-09-19 /pmc/articles/PMC6753512/ /pubmed/31555047 http://dx.doi.org/10.1177/1178223419864896 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
O’Halloran, Niamh
Khan, Sonja
Gilligan, Katie
Dwyer, Roisin
Kerin, Michael
Lowery, Aoife
Oncological Risk in Autologous Stem Cell Donation for Novel Tissue-Engineering Approaches to Postmastectomy Breast Regeneration
title Oncological Risk in Autologous Stem Cell Donation for Novel Tissue-Engineering Approaches to Postmastectomy Breast Regeneration
title_full Oncological Risk in Autologous Stem Cell Donation for Novel Tissue-Engineering Approaches to Postmastectomy Breast Regeneration
title_fullStr Oncological Risk in Autologous Stem Cell Donation for Novel Tissue-Engineering Approaches to Postmastectomy Breast Regeneration
title_full_unstemmed Oncological Risk in Autologous Stem Cell Donation for Novel Tissue-Engineering Approaches to Postmastectomy Breast Regeneration
title_short Oncological Risk in Autologous Stem Cell Donation for Novel Tissue-Engineering Approaches to Postmastectomy Breast Regeneration
title_sort oncological risk in autologous stem cell donation for novel tissue-engineering approaches to postmastectomy breast regeneration
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753512/
https://www.ncbi.nlm.nih.gov/pubmed/31555047
http://dx.doi.org/10.1177/1178223419864896
work_keys_str_mv AT ohalloranniamh oncologicalriskinautologousstemcelldonationfornoveltissueengineeringapproachestopostmastectomybreastregeneration
AT khansonja oncologicalriskinautologousstemcelldonationfornoveltissueengineeringapproachestopostmastectomybreastregeneration
AT gilligankatie oncologicalriskinautologousstemcelldonationfornoveltissueengineeringapproachestopostmastectomybreastregeneration
AT dwyerroisin oncologicalriskinautologousstemcelldonationfornoveltissueengineeringapproachestopostmastectomybreastregeneration
AT kerinmichael oncologicalriskinautologousstemcelldonationfornoveltissueengineeringapproachestopostmastectomybreastregeneration
AT loweryaoife oncologicalriskinautologousstemcelldonationfornoveltissueengineeringapproachestopostmastectomybreastregeneration